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Survival rates among HIV patients have significantly improved since the introduction of antiretroviral therapy (ART) in HIV
management. However, persistent disease progression and clinical complications in virally suppressed individuals point to
additional contributing factors other than HIV replication; microbial translocation is one such factor. The role of underlying
commensal microbes and microbial products that traverse the intestinal lumen into systemic circulation in the absence of overt
bacteraemia is under current investigation. This review focuses on current knowledge of the complex microbial communities and
microbial markers involved in the disruption of mucosal immune T-cells in the promotion of inflammatory processes in HIV
infections. Unanswered questions and aims for future studies are addressed. We provide perspective for discussing potential future
therapeutic strategies focused on modulating the gut microbiota to abate HIV disease progression.
1. Introduction
The human immunodeficiency virus (HIV), a lentivirus
and causal agent of acquired immunodeficiency syndrome
(AIDS), was first described in the early 1980s [1]. HIV
causes extensive, multifactorial dysregulation of the immune
system in infected individuals. The immune system becomes
compromised through a progressive depletion of CD4+ T-
lymphocytes (T-helper cells), macrophages, and dendritic
cells of the immune system, which gives rise to opportunis-
tic infections and disease. The rapid destruction of these
CD4+ T-cells primarily occurs in the mucosal tissue such
as the gut associated lymphoid tissues (GALT), harboring
an abundance of activated memory CD4+ T-cells [2]. This
destruction progresses to the peripheral tissues and blood
and continues within the next 7 to 10 years [3, 4].
The proposed involvement of gut microbiota in inflam-
matory processes that lead to disease progression such as
inflammatory bowel disease (IBD) [5] has been widely
reported in the literature [6]. There are over 100 trillion
bacterial cells in the human gut [7] and they serve as
providers of important metabolites for the host. Moreover,
they are active participants involved in the modulation of
host gene expression, maintenance of epithelial integrity, and
mediation of inflammatory and antimicrobial responses [8,
9]. Hence, the cumulative insult on the human innate and
adaptive immune system by HIV infection has been linked
to dysbiosis in the human gut bacteria [10, 11]. As such,
the translocation of intestinal bacteria and products into
systemic circulation has implicated roles in inflammation and
invariably immune activation [10, 12].
Several investigations point to the resident gutmicrobiota
as an integral driver of pathologic inflammation that persists
in patients even during the administration of antiretroviral
therapy (ART) [9, 13]. However, the mechanisms of human
gut microbiota involvement in inflammatory processes that
may influence disease progression in HIV are still poorly
elucidated. This understanding will be important in the
further development of effective therapies.
Recent studies implicate a potential causal relationship
between the composition of gutmicrobes and various human
disease conditions [14]. Observed clinical manifestations are
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attributed to the immune system, which, through complex
interactions, shapes and structures gut microbial commu-
nities [7]. In addition, nutritional or metabolic factors also
influence these structures [10]. Though capable of exerting
beneficial effects, the microbiota can also exacerbate disease
progression by directly or indirectly enhancing viral infec-
tion. The microbiota also plays vital roles in the maturation
of the specific immune system of the lymphoid organs, which
also serve as the first line of defence of the gastrointestinal
mucosa [14].
This review provides an update and a discussion on the
influence of the human gut microbiota in HIV infection and
disease progression. In the same vein, the influence of pre-
biotics and probiotics in the management of HIV infections
will be examined. Finally, unanswered questions relating gut
microbes and HIV progression and future perspectives for
achieving effective therapeutic strategies will be highlighted.
2. Gut Microbiota in Early HIV Infections
By definition, early HIV infection is the stage from infection
(undetectable viral load) and through the acute phase (clini-
cal manifestations of HIV observable), 3–5 days after infec-
tion. At this stage, rapid viral replication, intense immune
response, immune destruction, viral diversification [15, 16],
and CD4 cell count of greater than 200 cells/𝜇L [17–20] are
observed.The stage of infection is critical in the investigation
of microbiotal composition, and atypical microbiotas have
been observed in early stages of HIV infection [21].
In HIV infections, mucosal integrity is pertinent to dis-
ease progression, and similarly, viral infections are initiated
at points exposed to the surrounding environment, rife
with resident microorganisms [22]. Therefore, HIV infection
would have to negate both gut bacteria and epithelial barriers
to propagate infection.TheGALT,which harbors over 60%of
a person’s CD4+ T-cells, is impaired during the early stages of
HIV infection, suggesting an important role of the associated
mucosal microbiota in HIV infection and progression [12,
21]. In one study, higher levels of Enterobacteriales and
Bacteroidales correlated to the levels of GALT CD4+ T-cell
depletion and immune activation observed in HIV patients
compared to healthy controls [10]. Conversely, Gori et al.
[21] also observed overrepresentation of pathogenic species,
Candida albicans and Pseudomonas aeruginosa in early HIV
patients.These species have been implicated in opportunistic
infections observed in HIV-infected subjects [10, 21]. Species
such as bifidobacteria and lactobacilli, with propensities
to boost gut immune function by modulating the innate
immune system in pathogenic infection, are depleted in the
faecal microbiota of untreated HIV patients [20, 21, 23].
A shift in proportions of pathogenic and commensal
microbes relative to viral load has been observed, in some
studies involving other early stageHIVpatients, either treated
or untreated [24, 25]. Similarly, a recent study elucidated
imbalances in adherent gut bacterial communities in HIV-
infected subjects, either naive or treated with highly active
antiretroviral therapy (HAART) [25]. According to reports by
Vujkovic-Cvijin et al. there is a significant enrichment and
depletion of the Enterobacteriaceae family and Bacteroidia
class, respectively, in untreated HIV positive subjects com-
pared to treated subjects which either exhibited a profile of
bacterial composition similar to HIV− (healthy controls) or
HIV+ (infected) [25]. Thus, the progression of inflammation
symptoms in HIV patients showing suppressed viral loads
during ART could be explained by this effect of gut bacteria
species deemed to be proinflammatory. This observation
further underlines the potential involvement of microbiotal
composition in HIV progression.
Thus, studies elucidating imbalances in the gut micro-
biome associated with HIV infection have invariably incited
an interest to investigate the mechanisms of microbiota
involvement in the progression of this disease.Hence, current
and future research aims to explain the observed shift in
gut composition from protective species to proinflammatory,
disease-inducing bacterial species that create an environment
capable of promoting viral replication and chronic immune
activation. The specific clustering of microbiotas in diseased
and healthy control subjects and the dissimilar compositions
observed in patients treated with ART may also suggest
an important role for bacteria affecting viremia following
HIV infection [25]. However, the manner in which the
microbiota elicits immune activation in HIV subjects is
still poorly understood, and experimental studies seeking to
link gut resident bacteria with this phenomenon are highly
anticipated in the future.
3. Gut Microbiota in HIV Progression
Due to increased permeability of the intestinal barrier
observed in HIV-infected subjects, translocating microbes
or microbial products have been partially attributed to HIV
disease progression. Recent findings support this view and
progress towards understanding the role microbial translo-
cation plays in HIV/AIDS pathogenesis was achieved by
determining levels of systemic lipopolysaccharides (LPS) in
circulation [12]. LPS is a known activation factor of mono-
cytes modulating innate and adaptive immunity. Although
it does not directly account for all microbial translocation
[19], Brenchley et al. [12] demonstrated that it is bioactive
in vivo in mice. However, contradictory results have been
published that link microbial translocation and HIV disease
and progression in human subjects or animal models [26].
Redd et al. [27] demonstrated no correlation between LPS
levels and counts of soluble CD14 (sCD14), a coreceptor
in the recognition of bacterial LPS in systemic circulation.
In another study, increased levels of LPS were associated
with HIV infection in late stages [28, 29]. These contrary
findings indicate that microbial translocation is not the sole
driver of HIV progression. On the other hand, incongruence
among these studies may also result from differences in
experimental approaches in determining the levels of LPS
and sCD14 [26]. Either way, the massive loss of GIT lamina
propria CD4+ T-cells, the first target of HIV, may imply an
important role of the gutmicrobiota inHIVpathogenesis and
progression in later stages of the disease [30]. Similarly, an
earlier study reported the existence of a polymicrobic flora
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in blood samples of HIV-infected patients showing a poor
response to HAART and highlighting a damaged intestinal
barrier as the driving cause of microbial translocation [9,
23]. In another study, persistent T-cell hyperactivation was
attributed to disease progression in known immunologic
nonresponders to HAART and invariably hampered CD4+
T-cell reconstruction [31]. Hence, in late stages, the per-
sistence of peripheral T-cell immune activation and CD4
decline, coincidingwith the richness ofmicrobes ormicrobial
products in systemic circulation, has been implicated as a
predominate determinant of the disease progression rate in
HIV-infected patients [32]. Also, Hunt et al. showed that
T-cell activation remains persistent even during HAART
therapy and can be exacerbated with coinfections such as
hepatitis C [33]. This highlights that effective treatment
of HIV comorbidities is essential for management of HIV
disease progression. Although levels of bacterial rDNA in
plasma correlate with LPS levels and magnitude of immune
activation [34], the mechanisms by which HIV elicits T-cell
immune activation are still largely unknown [35].
As in other infections [36] microbial translocation occurs
in HIV infection [37] and certainly contributes to immune
activation [12]. Supposedly, other underlying factors other
than HIV are also implied in HIV progression, which may
includemicrobial translocation, directly or indirectly, in HIV
progression [9]. Although ART also seems to reduce the
levels of microbial translocation, restoring some GIT barrier
function, it does not completely revert HIV infection [12].
However, further investigation is needed to firmly establish
microbial translocation as a cause of HIV progression. It is
currently proposed that microbial translocation is a direct
consequence of HIV replication and its chronic immune
activation of the hosts’ immune system irrespective of viral
load reconstruction [12] and can otherwise be predictive
of disease severity [29]. It will therefore be of interest to
investigate any direct or indirect links of gut microbes and
microbial products in other non-AIDS related disorders such
as liver, cardiovascular, central nervous system, and cancer
diseases among others. A consequential effect of microbial
translocation is supported in most studies to date. For
example, in a recent study, Manner et al. [18] observed a
correlation between LPS levels and hypertension in HIV
subjects independent of CD4 cell counts. These non-AIDS
diseases have been significant contributors to morbidity
and mortality among HIV infected patients with greater
microbial translocation reported due to damaged intestinal
epithelium [17, 38].
Although a direct relationship betweenmicrobial translo-
cation andHIVdisease progressionmay seem to exist [26, 39]
especially in the chronic phase of the infection [12], it remains
clear that HIV itself fuels disease progression by initiating
a proinflammatory environment in the GIT and inflicting
damage on the mucosal barrier.
4. Disease Management by Pro- and Prebiotics
The compromised gut barrier in HIV infections results in
the loss of the mutually beneficial coevolving association
of gut epithelium and adherent bacteria. Therefore, inter-
vention therapy targeting the gut microbiota to curb HIV
progression has been proposed. Modulating the composition
of the microbiota is gaining prominence as a strategy for
future therapies. This is based on findings associating the
resident bacteria with immune activation. As such, studies
have been ascribed to certain bacterial species, roles in
maintaining epithelial mucosal integrity [40], and the early
maturation of the adaptive immune system [7, 21], and these
are being exploited in progut formulations [41]. HIV subjects
are known to have a compromised gut barrier function
and the observation that Bifidobacterium and Lactobacillus
species are depleted among the gut bacteria populations in
such patients [23] is consistent with earlier studies attribut-
ing improved gut barrier and immune function to these
species [42]. Essentially, certain strains of these beneficial
microbes have proven effective in maintaining gut barrier
function to ameliorate various diseases associated with GIT
inflammation [1]. Adequately administered probiotics (live
microorganisms that exert effects on health) can express
antimicrobial compounds such as bacteriocins that may kill
or inhibit the growth of pathogenic microbial species in the
gut, thus, conferring a net health benefit [1, 41]. Prebiotics
are also used to modulate resident gut homeostasis [41,
42]. Prebiotics are nondigestible food components such as
fiber or oligosaccharides, which selectively promote growth
of beneficial bacterial species. In this way, pathogenic gut
bacteria that maybe implicated in opportunistic infections,
a hallmark of HIV infection, are eliminated or reduced.
Treatments termed synbiotics, involving a combination of
both probiotics and prebiotics, have also been reported [41].
Although the mechanisms by which these treatments achieve
mucosal reconstruction are not completely elucidated, it is
believed to occur through the activity and recruitment of
natural killer cells [43]. Also, increases in tight junction
proteins as a response to the administration of VSL#3
probiotics (combination of eight bacterial species belonging
to Lactobacillus, Streptococcus, and Bifidobacterium genera)
have been demonstrated in vivo and in vitro [44].
At present, few studies report the use of prebiotics,
probiotics, or synbiotic dietary supplements in HIV therapy,
but their future use as a novel treatment strategy is gaining
support. According to a preliminary, placebocontrolled clin-
ical trial by Gori et al. [42], a mix of three oligosaccharide
prebiotics were effective inmodulating gutmicrobiota recon-
struction through the stimulation of bifidobacteria growth
and consequent reduction of pathogenic species. It resulted
in decreased sCD14 and LPS levels and activation of CD4+
T-cell and NK cells for at least 12 weeks in HIV-infected
adults naı¨ve to ART. In a similar study involving a probiotic
yogurt, the invasion of gastrointestinalmucosa by pathogenic
bacteria was completely inhibited [45].The L. rhamnosusGR-
1 stain supplement used in this study exhibited a significant
mucosal adhesive potential, as well as reduction of ARTdrug-
induced stomach pain in patients. This strain is generally
recognized as safe (GRAS) by the American Food and Drug
Administration, and it can, due to its adhesive properties,
inhibit or promote microbial translocation. Therefore, the
use of existing and novel probiotics formulations should be
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further investigated. Although long-term effects have not
been firmly established, positive correlations in modulating
gut bacteria and mucosa reconstruction were demonstrated
in a 25-week study using capsules of L. rhamnosus GR-1 and
L. reuteri RC-14 [43]. This study also showed that the time
during which the treatment is administered may determine
its measured efficacy.
An analysis of the key differentially expressed genes in
the colon, in response to a probiotic/prebiotic cocktail mix
in simian immunodeficiency virus (SIV) infected subjects,
revealed a significant upregulation of APC-associated gene
expression involved in T-cell immunity [46].Thesemacaques
were subsequently treated with antiretroviral (ARV) drugs.
This study therefore shows that, in addition to ARV, the syn-
biotic supplement has the potential to modulate GI immune
function by increasing gut CD4+T cells and reducing inflam-
mation. However, not all bacterial or oligosaccharide mixes
may be equally effective to clinically treat HIV infection. For
example, a placebocontrolled, clinical study administering
the synbiotic formulation Synbiotic 2000 that combines four
probiotic strains (Pediococcus pentosaceus 5-33:3, Leuconostoc
mesenteroides 32-77:1, Lactobacillus paracasei subsp. paraca-
sei 19, and Lactobacillus planetarium 2362) and four prebiotics
of nondigestible, fermentable fibers (beta glucan, inulin,
pectin, and resistant starch) for 4 weeks, to ART-treated
HIV patients resulted in unaltered plasma bacteria DNA
concentration and persistent immune activation, but levels of
the gut probiotic Lactobacillus species improved [47].
Other kinds of gut modulating formulations are also on
the rise. These orally ingested bioactive substances/mixes
can be taken with food [48] or as medical food [49]. To
examine the impact of orally delivered serum-derived bovine
immunoglobulin (SBI) on HIV enteropathy, Asmuth et al.
[49] recruited eight HIV patients on ART with chronic gas-
trointestinal symptoms. As stated, SBI was used distinctively
in clinical dietary management as commercially available
supplements, and it showed efficacy in modulating bowel
movements and increasing the density of CD4+ lymphocytes
in all subjects. These findings thus suggest that the modula-
tion of themucosa can have desirable effects in the restoration
and promotion of duodenal function and intestinal repair
[49].
5. Knowledge Gaps
Viral suppression by ART alone has been insufficient in the
clinical management of HIV. Therefore, it is imperative to
determine the role of the gut microbiota in HIV-induced
pathology, as microbial translocation, immune activation,
and gut inflammation may influence therapeutic efficacy.
Similarly, since LPS levels are difficult to measure [19],
methods presently employed to measure microbiota markers
associated with HIV infection and/or progression such as the
relationship between inflammation and translocation need to
be explored irrespective of LPS levels.
Various studies concur that the microbiota is involved
in HIV disease progression as a consequence of chronic
immunodeficiency [26]. In this light, the incorporation of
strategies targeting the microbiota in addition to the viral
load may prove quite effective in future clinical HIV ther-
apies. Probiotics, prebiotics or synbiotics have shown promis-
ing effects, though issues related to prolonged use, formu-
lation effectiveness, and universal immune preservation in
a geographically independent manner remain unresolved
[41]. Although these formulations are deemed effective and
improve gut function in HIV subjects, their role in modu-
lating mucosal immunity, circumventing the Th17 epithelial
barrier cells, is still largely unknown [22]. Also, clinical
trials incorporating larger study cohorts will afford increased
statistical bases to conclusively assess the effects of microbial
supplements on clinical outcomes of HIV infection. Probi-
otics and/or prebiotics are inexpensive and would represent
cost effective treatments for HIV patients, a clear advantage
in a global perspective given the economic status of regions
whereHIV ismost prevalent [41]. Similarly, novel therapeutic
strategies would be of particular interest in noncommuni-
cable HIV comorbidities (cardiovascular, bone, liver, central
nervous system). These disorders have been highlighted
as a major cause of morbidity even in ART-treated, HIV-
infected patients. Given that the mechanisms underlying this
comorbidity are proposed to be associated with immune
activation and microbial translocation, correlations with
effective therapeutic regimes should be pursued [50].
Other strategies could include directly treating microbes
or microbial products in patients with LPS nonproducing
bacteria or agents that bind LPS. Such would be aimed at
negating monocyte activation and the consequent triggering
of immune inflammation thereby curtailing further disease
progression [1]. Effective agents directing intestinal tract
immune activity such as the Toll-like cell receptors that
respond to microbial stimuli may also be targeted for intact
gut maintenance [12, 29]. However, existing knowledge of
the mechanism and interaction between the gut microbiota
and the mucosa are still lacking and would be fully explored.
Better understanding of the complex microbiome in HIV
infection will be crucial before the realization of these strate-
gies for the future. This can be achieved by incorporating
studies to expose immune tolerance strategies of patientswith
undetectable viraemia and the cases of HIV nonprogressors
[51].
Future studies should includemetagenomic evaluation to
elucidate microbial genes implicated in HIV disease progres-
sion. Also, it would be beneficial to design and perform large
descriptional studies of complex microbial communities in
HIV patients. Microbes play crucial roles in human biology
and harbor and express a greater number of genes in the
body than the host itself. Deciphering their contribution will
have a great impact on human health [11]. Recently, Pseu-
domonas fluorescens strain A506, a gut pathobiont marker,
was isolated and shown to be able to transform tryptophan to
kynurenine, thus overlapping the function of a human gene
[4]. Furthermore, advances in metagenomic approaches can
broaden our knowledge of microbial markers associated with
HIV by taking advantage of the enumerated human gut gene
catalogue, a part of the MetaHIT project [11]. In doing this, a
direct implication of gut microbiota in HIV progression may
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be elucidated by characterising human and microbial gene
functions and their overlaps.
6. Conclusions
In conclusion, HIV infections characteristically cause dam-
age to the gut mucosa, weakening the epithelial barrier,
compromising gut immunity, and exposing its host to a broad
range of microbial bioproducts that have been implicated
in the progression of HIV. Similarly, the gut microbiota is
severely impacted and the altered bacterial communities play
vital roles, directly or indirectly in HIV progression. ART
alone does not effectively control microbial translocation
through the gastrointestinal tract. The contribution of gut
microbes in HIV disease progression has been explored but
conclusive knowledge is lacking. Therefore, an increased
understanding of correlations between the proinflamma-
tory bacterial community composition and structure in the
human gut and HIV infection status can contribute to an
improved and holistic management of HIV progression.
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